According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

The plane maker is betting that demand for aircraft will continue to fuel growth in coming years. The systems will be jointly developed and produced by the two companies, with suppliers and industrial ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Sitting at her perch from the “Massachusetts Pavilion,” Gov. Maura Healey briefly gestured Tuesday to nearby competitors with flashy booths set up at the BIO International Convention, ...

Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly announced that the highest doses of tirzepatide (Zepbound) -- 12.5 mg and 15 mg -- will soon be available in single ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

US stocks are down after Trump had harsh words for Iran, saying he would not target the country's leader "for now." Fed's also meeting on policy.

Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.